BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 28663579)

  • 21. PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease.
    Li Z; Chen P; Su R; Hu C; Li Y; Elkahloun AG; Zuo Z; Gurbuxani S; Arnovitz S; Weng H; Wang Y; Li S; Huang H; Neilly MB; Wang GG; Jiang X; Liu PP; Jin J; Chen J
    Cancer Res; 2016 Feb; 76(3):619-29. PubMed ID: 26747896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Flt3 does not play a critical role in murine myeloid leukemias induced by MLL fusion genes.
    Albouhair S; Morgado E; Lavau C
    PLoS One; 2013; 8(8):e72261. PubMed ID: 23977266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. miR-101 suppresses the development of
    Gonzales-Aloy E; Connerty P; Salik B; Liu B; Woo AJ; Haber M; Norris MD; Wang J; Wang JY
    Haematologica; 2019 Jul; 104(7):e296-e299. PubMed ID: 30792205
    [No Abstract]   [Full Text] [Related]  

  • 24. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.
    Placke T; Faber K; Nonami A; Putwain SL; Salih HR; Heidel FH; Krämer A; Root DE; Barbie DA; Krivtsov AV; Armstrong SA; Hahn WC; Huntly BJ; Sykes SM; Milsom MD; Scholl C; Fröhling S
    Blood; 2014 Jul; 124(1):13-23. PubMed ID: 24764564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting epigenetic programs in MLL-rearranged leukemias.
    Bernt KM; Armstrong SA
    Hematology Am Soc Hematol Educ Program; 2011; 2011():354-60. PubMed ID: 22160057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia.
    Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ
    Int J Cancer; 2020 Apr; 146(7):1902-1916. PubMed ID: 31325323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.
    Deshpande AJ; Chen L; Fazio M; Sinha AU; Bernt KM; Banka D; Dias S; Chang J; Olhava EJ; Daigle SR; Richon VM; Pollock RM; Armstrong SA
    Blood; 2013 Mar; 121(13):2533-41. PubMed ID: 23361907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia.
    Jiang X; Huang H; Li Z; He C; Li Y; Chen P; Gurbuxani S; Arnovitz S; Hong GM; Price C; Ren H; Kunjamma RB; Neilly MB; Salat J; Wunderlich M; Slany RK; Zhang Y; Larson RA; Le Beau MM; Mulloy JC; Rowley JD; Chen J
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19397-402. PubMed ID: 23132946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond.
    Chen CW; Armstrong SA
    Exp Hematol; 2015 Aug; 43(8):673-84. PubMed ID: 26118503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
    Chen WL; Li DD; Chen X; Wang YZ; Xu JJ; Jiang ZY; You QD; Guo XK
    Eur J Med Chem; 2020 Feb; 188():112027. PubMed ID: 31923859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in acute myeloid leukemia.
    Röhrs S; Dirks WG; Meyer C; Marschalek R; Scherr M; Slany R; Wallace A; Drexler HG; Quentmeier H
    Mol Cancer; 2009 Oct; 8():86. PubMed ID: 19835597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1.
    Juszczynski P; Rodig SJ; Ouyang J; O'Donnell E; Takeyama K; Mlynarski W; Mycko K; Szczepanski T; Gaworczyk A; Krivtsov A; Faber J; Sinha AU; Rabinovich GA; Armstrong SA; Kutok JL; Shipp MA
    Clin Cancer Res; 2010 Apr; 16(7):2122-30. PubMed ID: 20332322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia.
    Chen Y; Jones KL; Anastassiadis K; Kranz A; Stewart AF; Grembecka J; Meyerson M; Ernst P
    Exp Hematol; 2019 Jan; 69():37-42. PubMed ID: 30315824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MLL-rearranged acute myeloid leukemia: Influence of the genetic partner in allo-HSCT response and prognostic factor of MLL 3' region mRNA expression.
    Burillo-Sanz S; Morales-Camacho RM; Caballero-Velázquez T; Carrillo E; Sánchez J; Pérez-López O; Pérez de Soto I; González Campos J; Prats-Martín C; Bernal R; Vargas MT
    Eur J Haematol; 2018 May; 100(5):436-443. PubMed ID: 29384595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).
    Fiskus W; Boettcher S; Daver N; Mill CP; Sasaki K; Birdwell CE; Davis JA; Takahashi K; Kadia TM; DiNardo CD; Jin Q; Qi Y; Su X; McGeehan GM; Khoury JD; Ebert BL; Bhalla KN
    Blood Cancer J; 2022 Jan; 12(1):5. PubMed ID: 35017466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MLL2, Not MLL1, Plays a Major Role in Sustaining MLL-Rearranged Acute Myeloid Leukemia.
    Chen Y; Anastassiadis K; Kranz A; Stewart AF; Arndt K; Waskow C; Yokoyama A; Jones K; Neff T; Lee Y; Ernst P
    Cancer Cell; 2017 Jun; 31(6):755-770.e6. PubMed ID: 28609655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel therapeutic strategies for MLL-rearranged leukemias.
    Wong NM; So CWE
    Biochim Biophys Acta Gene Regul Mech; 2020 Sep; 1863(9):194584. PubMed ID: 32534041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TGIF1 is a negative regulator of MLL-rearranged acute myeloid leukemia.
    Willer A; Jakobsen JS; Ohlsson E; Rapin N; Waage J; Billing M; Bullinger L; Karlsson S; Porse BT
    Leukemia; 2015 May; 29(5):1018-31. PubMed ID: 25349154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia.
    Wang E; Kawaoka S; Yu M; Shi J; Ni T; Yang W; Zhu J; Roeder RG; Vakoc CR
    Proc Natl Acad Sci U S A; 2013 Mar; 110(10):3901-6. PubMed ID: 23412334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia.
    Imayoshi N; Yoshioka M; Tanaka K; Yang SM; Akahane K; Toda Y; Hosogi S; Inukai T; Okada S; Maloney DJ; Nakahata T; Takita J; Kato I; Ashihara E
    Biochem Biophys Res Commun; 2022 Jan; 590():49-54. PubMed ID: 34971957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.